| A | B |
|---|---|
| Disease | |
| Brucellosis | • Arthritis. |
| • Cardiovascular, nervous, and respiratory system infections. | |
| • Chronic meningitis and meningoencephalitis. | |
| • Deafness. | |
| • Demyelinating meningovascular syndromes. | |
| • Episcleritis. | |
| • Fatigue, inattention, amnesia, and depression. | |
| • Guillain-Barré syndrome. | |
| • Hepatic abnormalities, including granulomatous hepatitis. | |
| • Multifocal choroiditis. | |
| • Myelitis-radiculoneuritis. | |
| • Nummular keratitis. | |
| • Papilledema. | |
| • Optic neuritis. | |
| • Orchioepididymitis and infections of the genitourinary system. | |
| • Sensorineural hearing loss. | |
| • Spondylitis. | |
| • Uveitis. | |
| Campylobacter jejuni | • Guillain-Barré syndrome if manifest within 2 months of the infection. |
| • Reactive Arthritis if manifest within 3 months of the infection. | |
| • Uveitis if manifest within 1 month of the infection. | |
| Coxiella burnetii (Q fever) | • Chronic hepatitis. |
| • Endocarditis. | |
| • Osteomyelitis. | |
| • Post-Q-fever chronic fatigue syndrome. | |
| • Vascular infection. | |
| Malaria | • Demyelinating polyneuropathy. |
| • Guillain-Barré syndrome. | |
| • Hematologic manifestations (particularly anemia after falciparum malaria and splenic rupture after vivax malaria). | |
| • Immune-complex glomerulonephritis. | |
| • Neurologic disease, neuropsychiatric disease, or both. | |
| • Ophthalmologic manifestations, particularly retinal hemorrhage and scarring. | |
| • Plasmodium falciparum. | |
| • Plasmodium malariae. | |
| • Plasmodium ovale. | |
| • Plasmodium vivax. | |
| • Renal disease, especially nephrotic syndrome. | |
| Mycobacterium tuberculosis | • Active tuberculosis. |
| • Long-term adverse health outcomes due to irreversible tissue damage from severe forms of pulmonary and extrapulmonary tuberculosis and active tuberculosis. | |
| Nontyphoid Salmonella | • Reactive Arthritis if manifest within 3 months of the infection. |
| Shigella | • Hemolytic-uremic syndrome if manifest within 1 month of the infection. |
| • Reactive Arthritis if manifest within 3 months of the infection. | |
| Visceral leishmaniasis | • Delayed presentation of the acute clinical syndrome. |
|
Code of Federal Regulations
252
|
|
| • Post-kala-azar dermal leishmaniasis if manifest within 2 years of the infection. | |
| • Reactivation of visceral leishmaniasis in the context of future immunosuppression. | |
| West Nile virus | • Variable physical, functional, or cognitive disability. |